A top student from Wuhan University has founded a company that has gone public, with investments from Tiger Global, Betta Pharmaceuticals, and Kingsray.

No products are currently available for sale.

Gelonghui FinanceDec 13 20:18

UBS Group: Reiterates AKESO (09926) 'Buy' rating with the Target Price raised to HKD 88.1.

UBS Group believes that the inclusion of AK112 and AK104 in the National Medical Insurance Pharmaceutical Directory (NRDL) in 2024 will drive the company's product sales growth next year.

Zhitong FinanceDec 13 11:37 · Ratings

UBS Group has raised the Target Price for AKESO (09926.HK) to 88.1 yuan, with strong momentum in research and development as well as commercialization.

UBS Group published a report indicating that AKESO (09926.HK) has made good progress in research and development as well as commercialization. The positive results from the ivonescimab (AK112) HARMONi-2 and cadonilimab (AK104) COMPASSION-15 studies have strengthened confidence in its Global market potential. Regarding the Business in mainland China, in addition to the soon-to-be-approved AK101 (IL-12/23), it is believed that the inclusion of AK112 and AK104 in the National Reimbursement Drug List (NRDL) in 2024 will drive the company's growth next year.

AASTOCKSDec 13 10:56

The "Major Banks" report by Jianyin International on the investment ratings and Target Prices for the top ten focused Hong Kong stocks (table).

Jianyin International released a research report, listing the investment ratings and target prices for the top ten focused Hong Kong stocks as follows: Stock | Investment Rating | Target Price (HKD) TENCENT (00700.HK) | Outperform the market | 557 HKD Meituan-W (03690.HK) | Outperform the market | 200 HKD JD.com-SW (09618.HK) | Outperform the market | 212.3 HKD AAC TECH (02018.HK) | Outperform the market | 40 HKD Xiaomi Group-W (01810.HK) | Outperform the market | 33 HKD China Pacific Insurance.

AASTOCKSDec 12 15:29

The tenth batch of Pharmaceutical centralized procurement in the mainland is about to begin bidding, with 62 types of Pharmaceuticals included in the national procurement.

The national Pharmaceutical procurement declaration information public conference will be held today (12th) in Shanghai, signaling the upcoming opening of bids for the tenth national Pharmaceutical concentrated procurement. This national procurement includes 62 types of Pharmaceuticals. Since the pilot for concentrated Pharmaceutical procurement launched in 2018 in four direct-controlled municipalities and seven sub-provincial cities, the process has gradually normalized. In recent years, it has generally occurred twice a year, while the tenth batch of procurement is the only national procurement for 2024. This national procurement includes 62 types of Pharmaceuticals, covering various disease areas such as cardiovascular and cerebrovascular, digestive, tumors, and metabolism, with more than half being injections sold through Hospital channels. The procurement cycle for each variety is determined by the selection results.

AASTOCKSDec 12 10:32

BOCOM INTL: Assigns a "Leading" rating to the domestic Pharmaceutical Industry. Shanghai establishes a 10 billion yuan M&A Fund, which is beneficial for accelerating industry consolidation.

BOCOM INTL believes that the pharmaceutical Sector still has further room for recovery.

Zhitong FinanceDec 12 10:20 · Ratings